Researchers are one step closer to creating a human vaccine for Helicobacter pylori, a bacterium found in 50% of the world's population that infects the stomach and causes chronic gastric inflammation, which can lead to ulcers and stomach cancer.
The Alzheimer's research field has been marked by one failure after another in pursuit of effective treatments, but Cambridge, MA-based NeuroPhage Pharmaceuticals thinks it can tackle the devastating disease with a novel approach.
A new antiviral drug may provide an effective way to treat measles in those who have not been vaccinated.
Many drugs used to treat lung, breast and pancreatic cancers also promote drug resistance and can ultimately spur tumor growth. Now, researchers may be able to predict which individual tumors will metastasize and spread when treated with certain drugs.
In a 1993 clinical trial of fialuridine--a drug originally designed as a therapy for hepatitis B--5 out of 15 patients died from sudden liver failure. A new study in PLOS Medicine found that mice with humanized livers demonstrate the drug's toxicity.
The ongoing Ebola outbreak in Western Africa underscores the critical need for better global surveillance strategies to combat the emergence of infectious diseases, especially those that have high mortality rates and pose a bioterror threat to countries, according to a new study.
A team of investigators has identified a new class of compounds that could work in a specific protein complex in the brain to provide a safe route toward reversing the devastating symptoms of Alzheimer's.
Scientists report that they have replicated a method of growing stem cells from adults using cloning techniques--a discovery that could help propel patient-specific regenerative therapies for a myriad of medical conditions and diseases.
A softer, plusher environment made of a key ingredient in Silly Putty may allow embryonic stem cells to grow faster and produce more specialized cells than traditional methods of making stem cells.
An experimental vaccine using a novel defense mechanism could eventually help treat sufferers of a common virus that affects more than half of the U.S. population and causes congenital birth defects in some cases.
A team of researchers from the U.S. and China has used 3-D printing to create a realistic model of a cancerous tumor.
Researchers may have discovered how a genetic mechanism in a common cause of Parkinson's works to destroy brain cells in patients--a finding that could help scientists develop new therapies for the devastating disease.
Researchers at the University of California, San Francisco, have launched a new online database to help reduce the time and cost of conducting clinical trials for brain ailments.
Scottish scientists report that they have successfully regenerated a living mouse organ and transplanted it into a young mouse.
A harmful gene mutation that increases a woman's risk of developing breast and ovarian cancer may also play a role in brain development, according to new findings by scientists at the Salk Institute for Biological Studies.
An analysis of nearly 4 million scientific articles has found that drug and disease research is disproportionately focused on medical conditions that predominantly afflict wealthy nations--such as diabetes, cancer and skin diseases--while less attention is given to diseases of the developing countries.
German and French researchers have found a key clue in how caffeine may work to protect the brain against the devastating effects of Alzheimer's disease.
Vitamin B-3, or niacin, is an essential human nutrient that has been used for more than 50 years to boost levels of HDL, or good cholesterol, in the blood. Now, new research suggests that a form of the vitamin might also be used to treat adult-onset mitochondrial muscle diseases.
The University of California, San Francisco, is teaming up with Japanese drugmaker Daiichi Sankyo for a drug-discovery pact focused on tackling neurodegenerative diseases.
The Lieber Institute for Brain Development is partnering with Astellas, Eli Lilly, Lundbeck, Pfizer and Roche to launch an early-stage research consortium to study the genetic mechanisms at work in brain disorders.